1z1r Citations

Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.

Abstract

High-resolution crystal structures are described for seven macrocycles complexed with HIV-1 protease (HIVPR). The macrocycles possess two amides and an aromatic group within 15-17 membered rings designed to replace N- or C-terminal tripeptides from peptidic inhibitors of HIVPR. Appended to each macrocycle is a transition state isostere and either an acyclic peptide, nonpeptide, or another macrocycle. These cyclic analogues are potent inhibitors of HIVPR, and the crystal structures show them to be structural mimics of acyclic peptides, binding in the active site of HIVPR via the same interactions. Each macrocycle is restrained to adopt a beta-strand conformation which is preorganized for protease binding. An unusual feature of the binding of C-terminal macrocyclic inhibitors is the interaction between a positively charged secondary amine and a catalytic aspartate of HIVPR. A bicyclic inhibitor binds similarly through its secondary amine that lies between its component N-terminal and C-terminal macrocycles. In contrast, the corresponding tertiary amine of the N-terminal macrocycles does not interact with the catalytic aspartates. The amine-aspartate interaction induces a 1.5 A N-terminal translation of the inhibitors in the active site and is accompanied by weakened interactions with a water molecule that bridges the ligand to the enzyme, as well as static disorder in enzyme flap residues. This flexibility may facilitate peptide cleavage and product dissociation during catalysis. Proteases [Aba67,95]HIVPR and [Lys7,Ile33,Aba67,95]HIVPR used in this work were shown to have very similar crystal structures.

Articles - 1z1r mentioned but not cited (2)



Reviews citing this publication (1)

  1. In search of an enzyme: the beta-secretase of Alzheimer's disease is an aspartic proteinase. Howlett DR, Simmons DL, Dingwall C, Christie G. Trends Neurosci 23 565-570 (2000)

Articles citing this publication (20)

  1. A new method to detect related function among proteins independent of sequence and fold homology. Schmitt S, Kuhn D, Klebe G. J Mol Biol 323 387-406 (2002)
  2. A new test set for validating predictions of protein-ligand interaction. Nissink JW, Murray C, Hartshorn M, Verdonk ML, Cole JC, Taylor R. Proteins 49 457-471 (2002)
  3. Substrate shape determines specificity of recognition for HIV-1 protease: analysis of crystal structures of six substrate complexes. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. Structure 10 369-381 (2002)
  4. How does a symmetric dimer recognize an asymmetric substrate? A substrate complex of HIV-1 protease. Prabu-Jeyabalan M, Nalivaika E, Schiffer CA. J Mol Biol 301 1207-1220 (2000)
  5. Inclusion of multiple fragment types in the site identification by ligand competitive saturation (SILCS) approach. Raman EP, Yu W, Lakkaraju SK, MacKerell AD. J Chem Inf Model 53 3384-3398 (2013)
  6. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. J Virol 78 12446-12454 (2004)
  7. Viability of a drug-resistant human immunodeficiency virus type 1 protease variant: structural insights for better antiviral therapy. Prabu-Jeyabalan M, Nalivaika EA, King NM, Schiffer CA. J Virol 77 1306-1315 (2003)
  8. Conformational constraint in protein ligand design and the inconsistency of binding entropy. Udugamasooriya DG, Spaller MR. Biopolymers 89 653-667 (2008)
  9. A novel family of predicted retroviral-like aspartyl proteases with a possible key role in eukaryotic cell cycle control. Krylov DM, Koonin EV. Curr Biol 11 R584-7 (2001)
  10. Mechanism of substrate recognition by drug-resistant human immunodeficiency virus type 1 protease variants revealed by a novel structural intermediate. Prabu-Jeyabalan M, Nalivaika EA, Romano K, Schiffer CA. J Virol 80 3607-3616 (2006)
  11. HIV-1 protease variants from 100-fold drug resistant clinical isolates: expression, purification, and crystallization. Vickrey JF, Logsdon BC, Proteasa G, Palmer S, Winters MA, Merigan TC, Kovari LC. Protein Expr Purif 28 165-172 (2003)
  12. A new structural theme in C2-symmetric HIV-1 protease inhibitors: ortho-substituted P1/P1' side chains. Wannberg J, Sabnis YA, Vrang L, Samuelsson B, Karlén A, Hallberg A, Larhed M. Bioorg Med Chem 14 5303-5315 (2006)
  13. Design and synthesis of broad-based mono- and bi- cyclic inhibitors of FIV and HIV proteases. Mak CC, Brik A, Lerner DL, Elder JH, Morris GM, Olson AJ, Wong CH. Bioorg Med Chem 11 2025-2040 (2003)
  14. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease. Specker E, Böttcher J, Brass S, Heine A, Lilie H, Schoop A, Müller G, Griebenow N, Klebe G. ChemMedChem 1 106-117 (2006)
  15. Prediction and analysis of binding affinities for chemically diverse HIV-1 PR inhibitors by the modified SAFE_p approach. Arenas M, Villaverde MC, Sussman F. J Comput Chem 30 1229-1240 (2009)
  16. Synthesis and extended activity of triazole-containing macrocyclic protease inhibitors. Pehere AD, Pietsch M, Gütschow M, Neilsen PM, Pedersen DS, Nguyen S, Zvarec O, Sykes MJ, Callen DF, Abell AD. Chemistry 19 7975-7981 (2013)
  17. From Structure to Function: A New Approach to Detect Functional Similarity among Proteins Independent from Sequence and Fold Homology. Schmitt S, Hendlich M, Klebe G. Angew Chem Int Ed Engl 40 3141-3144 (2001)
  18. Phenanthridine derivatives as potential HIV-1 protease inhibitors. Ershov PV, Мezentsev YV, Kaluzhskiy LA, Ivanov AS. Biomed Rep 13 66 (2020)
  19. Expected and unexpected results from combined beta-hairpin design elements. Dhanasekaran M, Prakash O, Gong YX, Baures PW. Org Biomol Chem 2 2071-2082 (2004)
  20. Efficient access to peptidyl ketones and peptidyl diketones via C-alkylations and C-acylations of polymer-supported phosphorus ylides followed by hydrolytic and/or oxidative cleavage. El-Dahshan A, Ahsanullah, Rademann J. Biopolymers 94 220-228 (2010)